Laboratoire de Physique et Chimie des Nano-objets

Institut National des Sciences Appliquées
135 avenue de Rangueil, 31077 TOULOUSE CEDEX 4 - FRANCE
Tél : 00 33 05 61 55 96 45 | Fax : (+33) (0)5 61 55 96 97

Partenaires

CNRS
INSA


Choose your site's language


          Version Française           English Version

Search

On this website



Home page > LPCNO > News > SWItchable Magneto-plasmonic contrast agents and MOlecular imaging Technologies

SWItchable Magneto-plasmonic contrast agents and MOlecular imaging Technologies

SWIMMOT will establish the scientific and technological basis for a radically new technique for in vivo molecular imaging based on a switchable contrast agent (CA) and corresponding optical imaging technology. Our CA will be based on novel magnetic core / plasmonic gold shell nanorods with specifically engineered biofunctional shells. We will develop a new magneto-plasmonic imaging technique based on magnetic excitation and plasmonic signal generation to realize multimodal optical coherence tomography / photoacoustic imaging modes. The magnetoplasmonic imaging technique will turn our CA on and off, which will allow complete removal of the imaging background. This discrimination of the background from the CA signal will yield ultra-high contrast molecular imaging. In addition, SWIMMOT, for the first time, will enable in vivo quantification of soluble biomarker concentrations and visualisation down to cellular resolution, which holds the potential to revolutionise molecular imaging and to surpass all current technological paradigms. These science and technology breakthroughs will enable detection of previously inaccessible in vivo physiology and molecular events, and elucidation of until now poorly understood biological mechanisms through studies in model organisms. This will in turn contribute to a better understanding of normal processes and disease pathogenesis. Thus, SWIMMOT will ultimately lead to earlier disease diagnostics for humans and to the development of new therapy concepts (including drugs). We will apply the SWIMMOT technology for diabetes research and will demonstrate its breakthrough potential for uncovering new biomolecular mechanisms in zebrafish model organisms. SWIMMOT is a four-year collaborative project that brings together five partners with complementary expertise: AIT Austrian Institute of Technology GmbH, Institut National des Sciences Appliquées de Toulouse, Universidad de Santiago de Compostela, Medizinische Universitaet Wien, Universitaet Innsbruck.